Drug Ther Bull. 2010 Nov;48(11):129-32. doi: 10.1136/dtb.2010.11.0057.
Malaria is a potentially life-threatening disease caused by protozoal parasites of the genus Plasmodium. It is mainly a problem in developing countries, and cases in the UK involve travellers coming from endemic areas. Resistance is increasing to several antimalarial drugs (e.g. chloroquine, mefloquine, antifolates). Another group of drugs, known as artemisinins, have come into widespread use more recently. An oral artemisinin-combination therapy (ACT) is now one of the standard licensed treatments for uncomplicated malaria in the UK. However, the parenteral artemisinin for severe malaria, artesunate, is not licensed in developed countries. Here we consider the role of artemisinins as treatment for malaria in the UK.
疟疾是由疟原虫属的原生动物寄生虫引起的一种潜在威胁生命的疾病。它主要是发展中国家面临的问题,在英国的病例涉及来自疟疾流行地区的旅行者。对几种抗疟药物(如氯喹、甲氟喹、抗叶酸剂)的耐药性正在增加。另一类药物,即青蒿素,最近已得到广泛应用。口服青蒿素联合疗法(ACT)现在是英国治疗非复杂性疟疾的标准许可治疗方法之一。然而,用于治疗重症疟疾的肠外青蒿素——青蒿琥酯,在发达国家未获许可。在此,我们探讨青蒿素在英国疟疾治疗中的作用。